TVTX - Back To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects Challenges | Benzinga
William Blair downgraded Travere Therapeutics Inc (NASDAQ: TVTX) to Market Perform.
Thursday, the company's head-to-head Phase 3 PROTECT Study of Filspari (sparsentan) in IgA nephropathy did not meet its confirmatory two-year endpoint of change from baseline in eGFR total slope compared to active comparator irbesartan at two years.
William Blair analysts Tim Lugo, Lachlan Hanbury-Brown, and John Boyle observe that although the confirmatory data for Filspari demonstrate a distinct advantage for patients, reinforcing the case for its ongoing marketing, these findings may offer limited motivation for payers to prefer ...